Please ensure Javascript is enabled for purposes of website accessibility

3 Growth Stocks That Could Put Facebook's Returns to Shame

By Tyler Crowe, Keith Speights, and Neha Chamaria – Updated Apr 18, 2018 at 8:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of Facebook have rewarded its investors incredibly well, but these Fools think you should take a look at these three stocks instead.

Facebook (META 5.37%) has been one of the great investment successes of this past decade. The company's social media platform has attracted billions in advertiser spending that has propelled it to become one of the most profitable companies out there. With Congress taking a deeper look at the company's business and the recent revelations about users' data privacy (or lack thereof), though, there are likely some investors out there looking to put money elsewhere. 

Though Facebook's performance over the past several years will be incredibly hard to replicate, we asked three of our contributors to sift through financial and business models to come up with three stocks that have a shot at meeting (or beating) Facebook's returns. Here's why they picked Vertex Pharmaceuticals (VRTX 2.69%), Cintas (CTAS 2.87%), and Cognex (CGNX 2.02%).

Stock chart and spreasheet superimposed over global map.

Image source: Getty Images.

Could beat Facebook? This stock already has

Keith Speights (Vertex Pharmaceuticals): Baseball legend Dizzy Dean once said, "It's not bragging if you can do it." One company that doesn't have to brag that it can beat Facebook's returns is Vertex Pharmaceuticals. The biotech stock nearly doubled Facebook's return last year and is performing significantly better than the social media giant so far in 2018, too.

Vertex currently enjoys a monopoly in treating cystic fibrosis (CF). Its drugs Kalydeco, Orkambi, and Symdeko correct malfunctions in the CFTR gene, which causes CF. Many CF patients have gene mutations that aren't addressed by these three drugs, though. However, Vertex thinks it will have effective treatments for roughly 90% of all CF patients within the next few years.

The biotech plans to achieve this goal through triple-drug combinations. Vertex already has a couple of late-stage studies of one triple-drug combo under way and plans to start a late-stage study of another combo in the next few months. AbbVie and Galapagos are also developing a triple-drug combo to treat CF, but Vertex should have a significant first-mover advantage. 

At a healthcare conference last month, Vertex CEO Jeff Leiden pointed out the company has a "problem": It's accumulating cash very rapidly. Vertex intends to address this "problem" by investing in innovation, both internally and through business development deals. The biotech is using its money to develop treatments for 10 other indications. Only one or two of those pipeline programs need to succeed for Vertex to continue beating Facebook's growth. 

Boring business can produce Facebook-type returns, too

Tyler Crowe (Cintas): Based on the statistics mentioned above, it would seem nearly impossible for any company to keep pace with Facebook. Shockingly, one company that has kept pace is on the complete opposite end of the business spectrum: uniform rental and facility services company Cintas.

It seems bizarre to think that such a business could produce the kind of stock price returns reserved for Sillicon Valley tech giants. Here's the crucial thing, though. Even though Cintas will never post gaudy revenue growth numbers, it is a high-margin, recurring revenue businesses. That in and of itself has led to impressive earnings growth over time. Unlike Facebook, which can plow billions into new developments, the industry in which Cintas operates is a mature one, so there is a limit to how much it can invest and expect a certain rate of return. With few other options for its cash, Cintas' management has for years elected to manufacture per-share returns with rising dividends and stock buybacks that have outpaced Facebook.

Here's how this works: Over the past decade, Cintas has grown net income by 120%. That's good, but when you combine it with Cintas' share buybacks that have reduced its share count, its earnings-per-share jumped 210% over that same time frame. Sprinkle in a dividend that has grown 13% annually, and you get a stock posting returns better than Facebook.  

Cintas is a boring, reliable business that's been around for a long time and has generated great returns for its investors. I can't imagine an investor who wouldn't be attracted to this kind of stock.

FB Total Return Price Chart

FB total return price. Data by YCharts.

Supercharged for the future 

Neha Chamaria (Cognex): Facebook stock has more than quadrupled since its initial public offering in 2012. During the same period, shares of Cognex -- a manufacturer of machine vision software and systems -- have grown almost sixfold.

Wait, what exactly is machine vision, you may ask. In its simplistic form, machine vision systems capture digital images that can be processed by computers to facilitate quick decision making. So for example, such a system could inspect thousands of machine parts per minute on a production line to detect and help eliminate defects in the least possible time and at the lowest cost. As you might have already guessed, Cognex's business has a lot to do with automation and robotics, and that's where the stock's potential lies.

During its last quarter, Cognex's sales jumped 39% year over year, but a net loss hit the stock. Blame it on a one-time charge under the new U.S. tax legislation -- otherwise, Cognex's net income shot up 46% year over year. 2017 was a record year for the company.

Management is increasingly bullish about growth, projecting sales from areas like 3D products and logistics to grow 50% annually in the near future. Meanwhile, markets like automotive and consumer electronics continue to grow at a strong clip as more and more companies are automating their processes. If you believe as I do that the artificial intelligence revolution is just getting started, don't be surprised if Cognex shares zoom past Facebook in the coming years.

Keith Speights owns shares of AbbVie and Facebook. Neha Chamaria has no position in any of the stocks mentioned. Tyler Crowe owns shares of Cintas. The Motley Fool owns shares of and recommends Cognex and Facebook. The Motley Fool recommends Cintas and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
META
$141.61 (5.37%) $7.21
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$292.41 (2.69%) $7.67
Cintas Corporation Stock Quote
Cintas Corporation
CTAS
$394.55 (2.87%) $11.02
Cognex Corporation Stock Quote
Cognex Corporation
CGNX
$43.50 (2.02%) $0.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.